Perforin-mediated lysis of tumor cells by Mycobacterium Bovis Bacillus Calmette-Guerin-activated killer cells

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3729-3738

  Brandau, S ^a   Suttmann, H ^a   Riemensberger, J ^a   Seitzer, U ^a   Arnold, J ^a   Durek, C ^a   Jocham, D ^a   Flad, H D ^a   Bohle, A ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; PERFORIN;

ANTINEOPLASTIC ACTIVITY; BLADDER TUMOR; CANCER IMMUNOTHERAPY; CYTOTOXICITY; HUMAN; HUMAN CELL; MYCOBACTERIUM BOVIS; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; TARGET CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD95; BCG VACCINE; CHO CELLS; CRICETINAE; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; HUMANS; INTERLEUKIN-2; KILLER CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MYCOBACTERIUM BOVIS; PORE FORMING CYTOTOXIC PROTEINS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0033822802     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors
2. A randomized trial of intravesical doxorubicin and immunotherapy with Bacillus Calmette-Guerin for transitional-cell carcinoma of the bladder
3. Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group study
4. BCG immunotherapy of bladder cancer: 20 years on
5. Presence of activated lymphocytes in the urine of patients after intravesical immunotherapy with Bacillus Calmette-Guerin
6. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with Bacillus Calmette-Guerin in superficial bladder cancer
7. Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical Bacillus Calmette-Guerin immunotherapy
8. Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical Bacillus Calmette-Guerin
9. Effects of local BCG therapy in patients with bladder carcinoma on phenotypes and function of mononuclear cells
10. Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall
11. Requirement of a thymus-dependent immune response for BCG-mediated antitumor activity
12. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer
13. LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: Possible mechanism of BCG therapy
14. Induction of Bacillus Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro
15. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines
16. Molecular mechanisms in cell-mediated cytotoxicity
17. The CTL's kiss of death
18. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
19. 2+-independent T cell-mediated cytotoxicity
20. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
21. Fas and perforin pathways as major mechanisms of T-cell mediated cytotoxicity
22. Perforin dependence of natural killer cell-mediated tumor control in vivo
23. Fas involvement in cytotoxicity mediated by human NK cells
24. Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity
25. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells
26. Natural killer (NK) cell-mediated cytotoxicity. Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells
27. The induction of Bacillus Calmette-Guerin-activated killer cells requires the presence of monocytes/macrophages and T-helper type 1 cells
28. Immunological mechanism of BCG-immunotherapy: Tumor cells are killed by perforin-releasing NK cells
29. Cytotoxicity of Bacillus Calmette-Guerin-activated killer cells towards bladder cells is specific for urothelial cells of cancerous origin
30. Comparative in vitro studies of the potentiation of tumor necrosis factor (TNF)-α, TNF-β, and TNF-SAM2 cytotoxicity by hyperthermia
31. Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity
32. Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived
33. Down-regulation of Fas ligand by shedding
34. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes)
35. Concanmycin A, a powerful tool for characterisation and estimation of contribution of perforin- and FAS-based lytic pathways in cell-mediated cytotoxicity
36. Acidification is essential for maintaining the structure and function of lytic granules of CTL
37. Activation and clonal expansion of tumor-specific effector cells
38. Metalloproteinase-mediated release of human Fas ligand
39. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases
40. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis. A possible mechanism of bystander cell death in HIV infection
41. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes
42. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V
43. Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte- mediated bladder tumour cell killing
44. An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines
45. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis
46. Perforin, Fas Ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells
47. 2+-dependent receptor molecule for lymphocyte perforin
48. Distinct T cell receptor signaling requirements for perforin- or FasL-mediated cytotoxicity
49. Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization
50. A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity
51. Molecular mechanisms of immune-mediated lysis of murine renal cancer: Differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells
52. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent
53. Alterations of FAS (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder